1 week Ago By ABMN Staff
Puma Biotechnology, Inc. ( NASDAQ:PBYI – Get Free Report ) insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.
15, for a total value of $29,726.55. Following the transaction, the insider now directly owns 108,951 shares of the company’s stock, valued at approximately $343,195.
65. The trade was a 7.97 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink . Puma Biotechnology Price Performance PBYI opened at $2.95 on Friday.
The stock has a market capitalization of $144.81 million, a P/E ratio of 6.15 and a beta of 1.
10. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.
42 and a quick ratio of 1.40. The company’s 50 day simple moving average is $2.
99 and its 200-day simple moving average is $2.98. Puma Biotechnology, Inc.
has a one year low of $2.22 and a one year high of $7.73.
Puma Biotechnology ( NASDAQ:PBYI – Get Free Report ) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.
31 by $0.10. The company had revenue of $80.
50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.
56% and a return on equity of 41.60%. During the same period in the prior year, the company posted $0.
12 EPS. Sell-side analysts anticipate that Puma Biotechnology, Inc. will post 0.
31 earnings per share for the current fiscal year. Institutional Trading of Puma Biotechnology Analyst Ratings Changes Several brokerages have weighed in on PBYI. HC Wainwright reaffirmed a “buy” rating and set a $7.
00 price objective on shares of Puma Biotechnology in a research note on Monday, December 23rd. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 6th.
Read Our Latest Stock Analysis on PBYI About Puma Biotechnology ( Get Free Report ) Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. Further Reading Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.
com's FREE daily email newsletter ..
